hC Bioscience Announces Program in Duchenne Muscular Dystrophy and Reports In Vivo Data from tRNA-based Protein Editing Platform
- Written by Newsfile
Boston, Massachusetts--(Newsfile Corp. - May 24, 2024) - hC Bioscience, a biopharmaceutical company developing a fundamentally novel approach to treating genetic diseases through tRNA-based protein editing, today announced preclinical data supporting its program in Duchenne muscular dystrophy (DMD) at the CureDuchenne FUTURES National...
